Salvage therapy versus upfront autologous stem cell transplantation in multiple myeloma patients with progressive disease after first-line induction therapy-Reference-Cited by-同舟云学术

Salvage therapy versus upfront autologous stem cell transplantation in multiple myeloma patients with progressive disease after first-line induction therapy

Published:2019-08-19 Issue:1 Volume:61 Page:27-36
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Blocka Joanna¹,Hielscher Thomas²,Mueller-Tidow Carsten¹,Goldschmidt Hartmut¹³,Hillengass Jens¹⁴

Affiliation:

1. Department of Hematology, Oncology and Rheumatology, University Hospital of Heidelberg, Heidelberg, Germany;

2. Department of Biostatistics, German Cancer Research Center, Heidelberg, Germany;

3. National Center for Tumor Diseases, Heidelberg, Germany;

4. Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2019.1646905

Reference23 articles.

1. HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA

2. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma

3. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma

4. Early myeloablative therapy for multiple myeloma

5. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing high dose melphalan;Blood Reviews;2023-12

2. Salvage Autologous Hematopoietic Stem Cell Transplantation Versus Chemoimmunotherapy in Relapsed Multiple Myeloma Patients After First Transplantation; Single Center Data;Journal of Ankara University Faculty of Medicine;2023-10-24

3. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy;Blood Advances;2023-08-10

4. Management of induction failures in newly diagnosed transplant-eligible multiple myeloma;Leukemia & Lymphoma;2019-09-10